News center | United States​

Philips demonstrates leadership in advanced respiratory and sleep patient care management at Medtrade Fall


  • ·   Announces upcoming milestone of 200,000 lives managed through Patient Adherence Management Services
  • ·   Showcases OSA and COPD management products, software and services; hosts executive forum featuring relevant industry topics

November 1, 2016

AMSTERDAM, the Netherlands and ATLANTA, Georgia – At this year’s Medtrade Fall, taking place in Atlanta, Ga. from October 31-November 3, Philips Respironics, a division of Royal Philips (NYSE: PHG, AEX: PHIA), will showcase its portfolio of integrated connected care software, solutions and services that aim to provide greater value to durable medical equipment (DME) providers and increase patient adherence to therapy. Philips will also host its first Fall Forum, aiming to engage industry leaders in discussions around the sleep and respiratory markets’ biggest challenges and opportunities.

 

During MedTrade Fall, Philips will showcase a variety of its sleep and respiratory solutions, including its Patient Adherence Management Services (PAMS) care management service. Developed with input from a leading behavioral scientist and designed for homecare providers looking for additional support in helping to improve sleep patient adherence, Philips’ PAMS has been shown to boost CPAP therapy adherence rates by 49 percent on average1. PAMS utilizes Philips Respironics EncoreAnywhere software, our widely used compliance management platform. PAMS is expected to reach the milestone of 200,000 lives managed through the service in mid-November.

 

“By developing connected health solutions, we’ve made it possible for physicians and home medical equipment (HME) providers to have more comprehensive insight into therapy use and efficacy. This allows them to adjust therapeutic settings or intervene to help patients be successful in therapy longer. We use this same technology to drive PAMS,” said Jim Doty, the senior field marketing director at Philips Respironics. “Through innovative connected platforms, including our recently introduced Care Orchestrator clinical management solution, we aim to achieve a transformative impact on the homecare industry similar to the impact EncoreAnywhere had 10 years ago as the first cloud based patient management system.”

 

During the show, beyond PAMS, attendees will have the opportunity to see some of the latest innovations from Philips Respironics in sleep and respiratory care, including:

  • Care Orchestrator: A first-of-its-kind connected health technology, Care Orchestrator will connect with Philips sleep and respiratory devices and other relevant patient data, including billing and insurance information and electronic health records;
  • SimplyGo Mini: The smallest and lightest POC in the Philips portfolio;
  • Trilogy ventilator with AVAPS-AE: The most widely dispensed ventilator for home use in United States2, designed to meet the needs of the respiratory failure patient with enhanced comfort and synchrony in breathing and
  • Sleep therapy solutions, including: The Dream Family OSA products, Amara View mask and the new Wisp Pediatric Nasal mask.

 

Additionally, Philips will be organizing its first Fall Forum at the Philips Medtrade Fall booth. Short presentations will provide attendees an overview of the sleep and respiratory care industries’ challenges and opportunities, showcasing Philips solutions as case studies. Topics include:

  • “The Latest Advances in Sleep Therapy Adherence Solutions,” presented by Segment Director for Services, Anthony Como
  • “Introducing Care Orchestrator – The Future of Connected Solutions,” presented by Bob Barker, Director of Product Management, New Business Solutions
  • “Improving COPD Patient Management,” presented by Rusty Trim, RRT, Sr. Field Marketing Manager, Sleep and Home Respiratory

 

A full list of topics featured in the Fall Forum can be found here.

 

Visit Philips at booth #1919 at Medtrade Fall at the Georgia World Congress Center in Atlanta, Ga. For more information on Philips’ advanced solutions for sleep and respiratory care and updates from the show visit www.respironics.com or follow @PhilipsResp.

 

 

 

1 Retrospective study using 2014 -2016 EncoreAnywhere data from 12 Home Care Providers that used PAMS for at least six months. CMS Compliance definition - minimum of 4 hours of use over 70% of the nights during a consecutive 30 day period within the first 90 days of use.

2 Philips–sponsored market survey study of 120 DMEs on the brands of ventilators the DMEs set-up for patients in May 2016.

For further information, please contact:

Kathy O’Reilly

Philips Group Communications

Tel.: +1 978-659-2638

Mobile: +1 978-221-8919 

E-mail: Kathy.Oreilly@philips.com

Twitter: @kathyoreilly

About Royal Philips:

 

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company, headquartered in the Netherlands, is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

 

About Philips Respironics

 

Philips Respironics is a global leader in the sleep and respiratory care markets, offering solutions in sleep apnea management, oxygen therapy, noninvasive ventilation and respiratory drug delivery and has a long history of leading new innovation in both devices and informatics solutions to help patients sleep and breathe better.

You are about to visit a Philips global content page

Continue

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.